Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients

Elena Giacomini, Fabiana Rizzo, Marilena P. Etna, Melania Cruciani, Rosella Mechelli, Maria Chiara Buscarinu, Francesca Pica, Cartesio D’Agostini, Marco Salvetti, Eliana M. Coccia, Martina Severa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: B cells are key pathogenic effectors in multiple sclerosis (MS) and several therapies have been designed to restrain B cell abnormalities by directly targeting this lymphocyte population. Objectives: Moving from our data showing a Toll-like receptor (TLR)7-driven dysregulation of B cell response in relapsing–remitting multiple sclerosis (RRMS) and having found a low serum level of Thymosin-α1 (Tα1) in patients, we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets, known to dampen autoimmune inflammation. Methods: Serum Tα1 level was measured by enzyme immunoassay. Cytokine expression was evaluated by Cytometric Bead Array (CBA), enzyme-linked immunosorbent assay (ELISA), and real-time reverse transcription polymerase chain reaction (RT-PCR). B cell subsets were analyzed by flow cytometry. Results: Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35. Indeed, Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets, which likely inhibit both interferon (IFN)-γ and IL-17 production. Conclusion:: Our study reveals a deficient ability of B cells from MS patients to differentiate into regulatory subsets and unveils a novel anti-inflammatory and repurposing potential for Tα1 in MS targeting B cell response.

Original languageEnglish
JournalMultiple Sclerosis Journal
DOIs
Publication statusAccepted/In press - Feb 1 2017

Fingerprint

Regulatory B-Lymphocytes
Thymosin
B-Lymphocyte Subsets
Interleukin-10
Multiple Sclerosis
B-Lymphocytes
Blood Cells
Anti-Inflammatory Agents
Toll-Like Receptor 7
Interleukin-17
Interleukins
Serum
Immunoenzyme Techniques
Interleukin-8
Interleukin-1
Interferons
Reverse Transcription
Interleukin-6
Flow Cytometry
Therapeutics

Keywords

  • B-lymphocytes
  • Multiple sclerosis
  • regulatory
  • thymosin alpha1

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients. / Giacomini, Elena; Rizzo, Fabiana; Etna, Marilena P.; Cruciani, Melania; Mechelli, Rosella; Buscarinu, Maria Chiara; Pica, Francesca; D’Agostini, Cartesio; Salvetti, Marco; Coccia, Eliana M.; Severa, Martina.

In: Multiple Sclerosis Journal, 01.02.2017.

Research output: Contribution to journalArticle

Giacomini, Elena ; Rizzo, Fabiana ; Etna, Marilena P. ; Cruciani, Melania ; Mechelli, Rosella ; Buscarinu, Maria Chiara ; Pica, Francesca ; D’Agostini, Cartesio ; Salvetti, Marco ; Coccia, Eliana M. ; Severa, Martina. / Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients. In: Multiple Sclerosis Journal. 2017.
@article{8a82a5fdce654f0fb7c9cf6ce55087c1,
title = "Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients",
abstract = "Background: B cells are key pathogenic effectors in multiple sclerosis (MS) and several therapies have been designed to restrain B cell abnormalities by directly targeting this lymphocyte population. Objectives: Moving from our data showing a Toll-like receptor (TLR)7-driven dysregulation of B cell response in relapsing–remitting multiple sclerosis (RRMS) and having found a low serum level of Thymosin-α1 (Tα1) in patients, we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets, known to dampen autoimmune inflammation. Methods: Serum Tα1 level was measured by enzyme immunoassay. Cytokine expression was evaluated by Cytometric Bead Array (CBA), enzyme-linked immunosorbent assay (ELISA), and real-time reverse transcription polymerase chain reaction (RT-PCR). B cell subsets were analyzed by flow cytometry. Results: Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35. Indeed, Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets, which likely inhibit both interferon (IFN)-γ and IL-17 production. Conclusion:: Our study reveals a deficient ability of B cells from MS patients to differentiate into regulatory subsets and unveils a novel anti-inflammatory and repurposing potential for Tα1 in MS targeting B cell response.",
keywords = "B-lymphocytes, Multiple sclerosis, regulatory, thymosin alpha1",
author = "Elena Giacomini and Fabiana Rizzo and Etna, {Marilena P.} and Melania Cruciani and Rosella Mechelli and Buscarinu, {Maria Chiara} and Francesca Pica and Cartesio D’Agostini and Marco Salvetti and Coccia, {Eliana M.} and Martina Severa",
year = "2017",
month = "2",
day = "1",
doi = "10.1177/1352458517695892",
language = "English",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients

AU - Giacomini, Elena

AU - Rizzo, Fabiana

AU - Etna, Marilena P.

AU - Cruciani, Melania

AU - Mechelli, Rosella

AU - Buscarinu, Maria Chiara

AU - Pica, Francesca

AU - D’Agostini, Cartesio

AU - Salvetti, Marco

AU - Coccia, Eliana M.

AU - Severa, Martina

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: B cells are key pathogenic effectors in multiple sclerosis (MS) and several therapies have been designed to restrain B cell abnormalities by directly targeting this lymphocyte population. Objectives: Moving from our data showing a Toll-like receptor (TLR)7-driven dysregulation of B cell response in relapsing–remitting multiple sclerosis (RRMS) and having found a low serum level of Thymosin-α1 (Tα1) in patients, we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets, known to dampen autoimmune inflammation. Methods: Serum Tα1 level was measured by enzyme immunoassay. Cytokine expression was evaluated by Cytometric Bead Array (CBA), enzyme-linked immunosorbent assay (ELISA), and real-time reverse transcription polymerase chain reaction (RT-PCR). B cell subsets were analyzed by flow cytometry. Results: Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35. Indeed, Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets, which likely inhibit both interferon (IFN)-γ and IL-17 production. Conclusion:: Our study reveals a deficient ability of B cells from MS patients to differentiate into regulatory subsets and unveils a novel anti-inflammatory and repurposing potential for Tα1 in MS targeting B cell response.

AB - Background: B cells are key pathogenic effectors in multiple sclerosis (MS) and several therapies have been designed to restrain B cell abnormalities by directly targeting this lymphocyte population. Objectives: Moving from our data showing a Toll-like receptor (TLR)7-driven dysregulation of B cell response in relapsing–remitting multiple sclerosis (RRMS) and having found a low serum level of Thymosin-α1 (Tα1) in patients, we investigated whether the addition of this molecule to peripheral blood mononuclear cells (PBMCs) would influence the expansion of regulatory B cell subsets, known to dampen autoimmune inflammation. Methods: Serum Tα1 level was measured by enzyme immunoassay. Cytokine expression was evaluated by Cytometric Bead Array (CBA), enzyme-linked immunosorbent assay (ELISA), and real-time reverse transcription polymerase chain reaction (RT-PCR). B cell subsets were analyzed by flow cytometry. Results: Tα1 pre-treatment induces an anti-inflammatory status in TLR7-stimulated RRMS PBMC cultures, reducing the secretion of pro-inflammatory interleukin (IL)-6, IL-8, and IL-1β while significantly increasing the regulatory IL-10 and IL-35. Indeed, Tα1 treatment enhanced expansion of CD19+CD24+CD38hi transitional-immature and CD24low/negCD38hi plasmablast-like regulatory B cell subsets, which likely inhibit both interferon (IFN)-γ and IL-17 production. Conclusion:: Our study reveals a deficient ability of B cells from MS patients to differentiate into regulatory subsets and unveils a novel anti-inflammatory and repurposing potential for Tα1 in MS targeting B cell response.

KW - B-lymphocytes

KW - Multiple sclerosis

KW - regulatory

KW - thymosin alpha1

UR - http://www.scopus.com/inward/record.url?scp=85043324009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043324009&partnerID=8YFLogxK

U2 - 10.1177/1352458517695892

DO - 10.1177/1352458517695892

M3 - Article

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -